Brokerages Set Liquidia Co. (NASDAQ:LQDA) PT at $23.14

Shares of Liquidia Co. (NASDAQ:LQDA) have been assigned an average recommendation of “Moderate Buy” from the eight brokerages that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $23.14.

Several analysts have recently commented on the stock. Needham & Company LLC restated a “buy” rating and issued a $25.00 target price on shares of Liquidia in a research note on Monday, August 19th. Raymond James raised Liquidia from an “outperform” rating to a “strong-buy” rating in a report on Monday, August 19th. BTIG Research cut their target price on Liquidia from $29.00 to $25.00 and set a “buy” rating for the company in a research note on Monday, August 19th. Bank of America decreased their price target on Liquidia from $24.00 to $23.00 and set a “buy” rating on the stock in a research note on Tuesday, August 20th. Finally, Oppenheimer initiated coverage on Liquidia in a research report on Tuesday, June 25th. They issued a “market perform” rating for the company.

Liquidia Stock Up 0.8 %

Shares of LQDA stock opened at $9.80 on Friday. The stock’s 50-day moving average price is $11.00 and its 200 day moving average price is $12.68. The stock has a market capitalization of $748.48 million, a PE ratio of -6.28 and a beta of 0.22. Liquidia has a 52-week low of $5.71 and a 52-week high of $16.99.

Liquidia (NASDAQ:LQDA) last released its earnings results on Wednesday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). Liquidia had a negative net margin of 755.46% and a negative return on equity of 183.57%. The company had revenue of $3.66 million during the quarter, compared to analyst estimates of $7.92 million. Analysts expect that Liquidia will post -1.69 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Caligan Partners Lp purchased 150,000 shares of the business’s stock in a transaction dated Friday, August 30th. The stock was acquired at an average price of $9.51 per share, with a total value of $1,426,500.00. Following the purchase, the director now directly owns 6,994,997 shares of the company’s stock, valued at approximately $66,522,421.47. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CFO Michael Kaseta sold 3,906 shares of the firm’s stock in a transaction that occurred on Friday, July 12th. The shares were sold at an average price of $12.53, for a total transaction of $48,942.18. Following the completion of the transaction, the chief financial officer now directly owns 312,389 shares of the company’s stock, valued at approximately $3,914,234.17. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Caligan Partners Lp bought 150,000 shares of Liquidia stock in a transaction that occurred on Friday, August 30th. The stock was bought at an average cost of $9.51 per share, for a total transaction of $1,426,500.00. Following the purchase, the director now owns 6,994,997 shares in the company, valued at approximately $66,522,421.47. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 21,422 shares of company stock worth $256,998. 31.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Liquidia

Several hedge funds have recently bought and sold shares of LQDA. Quest Partners LLC purchased a new stake in Liquidia during the 2nd quarter worth about $27,000. Hilltop National Bank acquired a new position in shares of Liquidia in the second quarter valued at approximately $33,000. Deuterium Capital Management LLC acquired a new position in shares of Liquidia in the second quarter valued at approximately $120,000. DMC Group LLC acquired a new stake in Liquidia during the second quarter worth approximately $122,000. Finally, Whitcomb & Hess Inc. purchased a new stake in Liquidia in the 2nd quarter worth approximately $126,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).